Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.39 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.39 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.30 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.30 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL987953 | 0.96 | HSD17B10 (0.45) | HSD17B10MEN1KMT2ATHRBHTT | |
| SCHEMBL987771 | 0.96 | HSD17B10 (0.45) | HSD17B10MEN1KMT2ATHRBHTT | |
| SCHEMBL438257 | 0.96 | HSD17B10 (0.45) | HSD17B10MEN1KMT2ATHRBHTT | |
| SCHEMBL7799602 | 0.96 | HSD17B10 (0.45) | HSD17B10MEN1KMT2ATHRBHTT | |
| Water SCHEMBL482851 | 0.96 | — | — | |
| SCHEMBL272664 | 0.96 | HSD17B10 (0.45) | HSD17B10MEN1KMT2ATHRBHTT | |
| SCHEMBL17586846 | 0.96 | HSD17B10 (0.45) | HSD17B10MEN1KMT2ATHRBHTT | |
| SCHEMBL116376 | 0.96 | HSD17B10 (0.45) | HSD17B10MEN1KMT2ATHRBHTT | |
| SCHEMBL12570287 | 0.96 | HSD17B10 (0.45) | HSD17B10MEN1KMT2ATHRBHTT | |
| SCHEMBL9183077 | 0.96 | HSD17B10 (0.45) | HSD17B10MEN1KMT2ATHRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114957-A2 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | IPCA Laboratories Limited (IN) | 2009-11-11 | — | — | EP | claimed |
| US-20080188663-A1 | Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I | IPCA LABORATORIES LIMITED (IN) | 2008-08-07 | — | — | US | claimed |
| WO-2008093357-A2 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | IPCA LABORATORIES LIMITED (IN) | 2008-08-07 | — | — | WO | claimed |
| US-20100081839-A1 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | IPCA LABORATORIES LTD. (IN) | 2010-04-01 | — | — | US | disclosed |
| US-20100081839-A1 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | IPCA LABORATORIES LTD. (IN) | 2010-04-01 | — | — | US | disclosed |
| EP-2114957-A2 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | IPCA Laboratories Limited (IN) | 2009-11-11 | — | — | EP | disclosed |
| EP-2114957-A2 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | IPCA Laboratories Limited (IN) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008093357-A3 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | IPCA LAB LTD (IN) | 2008-12-04 | — | — | WO | disclosed |
| US-20080188663-A1 | Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I | IPCA LABORATORIES LIMITED (IN) | 2008-08-07 | — | — | US | disclosed |
| US-20080188663-A1 | Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I | IPCA LABORATORIES LIMITED (IN) | 2008-08-07 | — | — | US | disclosed |
| WO-2008093357-A2 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | IPCA LABORATORIES LIMITED (IN) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008093357-A2 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | IPCA LABORATORIES LIMITED (IN) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081839-A1 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | VKORC1, VKORC1L1, PTGER1 | MEN1 3211/4885THRB 3770/4885ADRB2 672/4885 |
| US-20080188663-A1 | Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I | CYP2S1, CYP2F1, VKORC1L1 | MEN1 4084/4885THRB 4427/4885ADRB2 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.